

Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/H98AB9446C1AEN.html>

Date: August 2022

Pages: 81

Price: US\$ 2,000.00 (Single User License)

ID: H98AB9446C1AEN

Abstracts

Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, Preclinical and Unknown stages are 12, 6, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 4 molecules, respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hairy Cell Leukemia - Overview
- Hairy Cell Leukemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hairy Cell Leukemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hairy Cell Leukemia - Companies Involved in Therapeutics Development
- AbbVie Inc
- Ascentage Pharma Group International
- AstraZeneca Plc
- Autolus Therapeutics Plc
- Bristol-Myers Squibb Co
- Eureka Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Incyte Corp
- Jecho Biopharmaceuticals Co Ltd
- MacroGenics Inc
- Mediolanum farmaceutici SpA
- Mustang Bio Inc
- Novartis AG
- Sorrento Therapeutics Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Xi'An Yufan Biotechnology Co Ltd
- Xynomic Pharmaceuticals Holdings Inc
- Hairy Cell Leukemia - Drug Profiles
- abivertinib maleate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events

acalabrutinib maleate - Drug Profile

Product Description

Mechanism Of Action

History of Events

APG-2575 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AUTO-1NG - Drug Profile

Product Description

Mechanism Of Action

History of Events

CDMO-002 - Drug Profile

Product Description

Mechanism Of Action

cobimetinib fumarate - Drug Profile

Product Description

Mechanism Of Action

History of Events

dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile

Product Description

Mechanism Of Action

History of Events

dezapelisib - Drug Profile

Product Description

Mechanism Of Action

History of Events

ELB-021 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ET-019002 - Drug Profile

Product Description

Mechanism Of Action

GEM-155 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Leukemia or Lymphoma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD19 for Lymphoma and Leukemia - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD19 for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Target CD20 for Oncology - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD22 for Oncology - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Target CD22 for Oncology - Drug Profile

Product Description

Mechanism Of Action

History of Events

ibrutinib - Drug Profile

Product Description

Mechanism Of Action

History of Events

interferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

itacitinib adipate - Drug Profile

Product Description

Mechanism Of Action

History of Events

MB-106 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MGD-024 - Drug Profile

Product Description

Mechanism Of Action

moxetumomab pasudotox - Drug Profile

Product Description

Mechanism Of Action

History of Events

obinutuzumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Onureg - Drug Profile

Product Description

Mechanism Of Action

History of Events

paracclisib - Drug Profile

Product Description

Mechanism Of Action

History of Events

vemurafenib - Drug Profile

Product Description

Mechanism Of Action

History of Events

XP-102 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Hairy Cell Leukemia - Dormant Projects

Hairy Cell Leukemia - Discontinued Products

Hairy Cell Leukemia - Product Development Milestones

Featured News & Press Releases

Jul 21, 2021: Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia

May 19, 2021: ESMO: BRAF inhibitor and Rituximab for the management of refractory or relapsed HCL

Dec 10, 2020: CHMP adopts a positive opinion for the medicinal product Lumoxiti for the treatment of relapsed or refractory hairy cell leukaemia

Jan 02, 2020: The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia

Dec 08, 2019: Innate Pharma highlights FDA-approved Lumoxiti at ASH 2019

Nov 07, 2019: Innate Pharma to share new long-term data on Lumoxiti at 2019 American Society of Hematology annual meeting

May 08, 2019: A patient's 10-year journey to moxetumomab for hairy cell leukemia

Mar 12, 2019: Innate Pharma announces the appointment of Jennifer Butler appointed as executive vice president, general manager, US

Nov 27, 2018: AstraZeneca to present on Lumoxiti 2018 American Society of Hematology Annual Meeting

Nov 02, 2018: Novartis to present data on Dabrafenib and Trametinib combination at 2018 ASH annual meeting

Sep 17, 2018: AstraZeneca's Lumoxiti secures FDA nod to treat hairy cell leukaemia

Jun 02, 2018: Moxetumomab Pasudotox Pivotal Data in Patients with Previously-Treated Hairy Cell Leukemia Presented at the 2018 ASCO Meeting

Apr 03, 2018: US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukaemia

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hairy Cell Leukemia - Pipeline by AbbVie Inc, 2022
Hairy Cell Leukemia - Pipeline by Ascentage Pharma Group International, 2022
Hairy Cell Leukemia - Pipeline by AstraZeneca Plc, 2022
Hairy Cell Leukemia - Pipeline by Autolus Therapeutics Plc, 2022
Hairy Cell Leukemia - Pipeline by Bristol-Myers Squibb Co, 2022
Hairy Cell Leukemia - Pipeline by Eureka Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Hairy Cell Leukemia - Pipeline by Incyte Corp, 2022
Hairy Cell Leukemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by MacroGenics Inc, 2022
Hairy Cell Leukemia - Pipeline by Mediolanum farmaceutici SpA, 2022
Hairy Cell Leukemia - Pipeline by Mustang Bio Inc, 2022
Hairy Cell Leukemia - Pipeline by Novartis AG, 2022
Hairy Cell Leukemia - Pipeline by Sorrento Therapeutics Inc, 2022
Hairy Cell Leukemia - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xi'An Yufan Biotechnology Co Ltd, 2022
Hairy Cell Leukemia - Pipeline by Xynomic Pharmaceuticals Holdings Inc, 2022
Hairy Cell Leukemia - Dormant Projects, 2022
Hairy Cell Leukemia - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hairy Cell Leukemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Hairy Cell Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/H98AB9446C1AEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H98AB9446C1AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

